Gabapentin’s story began as a scientific triumph, a targeted therapy for epilepsy that soon expanded into a widely used treatment for nerve pain, sciatica, and chronic back pain. Its spread was quiet but massive; prescriptions soared, and it became part of everyday medicine cabinets. Now, the Case Western Reserve University study has forced an unsettling question into the open: what if long-term relief carries a hidden cognitive bill? A 29% higher dementia risk among those with repeated prescriptions is not a number that can be easily ignored.

Yet the truth is more complicated than a simple villain. Chronic pain itself erodes memory, mood, and mobility. Low physical activity, common in long-term pain sufferers, is already a known dementia risk. Researchers stress this is correlation, not proof of harm. The real message is vigilance: patients must ask harder questions, and clinicians must weigh comfort today against clarity tomorrow.